312 related articles for article (PubMed ID: 32687161)
1. A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults.
Moon JE; Ockenhouse C; Regules JA; Vekemans J; Lee C; Chuang I; Traskine M; Jongert E; Ivinson K; Morelle D; Komisar JL; Lievens M; Sedegah M; Garver LS; Sikaffy AK; Waters NC; Ballou WR; Ofori-Anyinam O;
J Infect Dis; 2020 Oct; 222(10):1681-1691. PubMed ID: 32687161
[TBL] [Abstract][Full Text] [Related]
2. A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01
Moon JE; Greenleaf ME; Regules JA; Debois M; Duncan EH; Sedegah M; Chuang I; Lee CK; Sikaffy AK; Garver LS; Ivinson K; Angov E; Morelle D; Lievens M; Ockenhouse CF; Ngauy V; Ofori-Anyinam O;
Vaccine; 2021 Oct; 39(43):6398-6406. PubMed ID: 34593270
[TBL] [Abstract][Full Text] [Related]
3. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi.
Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A
Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383
[TBL] [Abstract][Full Text] [Related]
4. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.
Regules JA; Cicatelli SB; Bennett JW; Paolino KM; Twomey PS; Moon JE; Kathcart AK; Hauns KD; Komisar JL; Qabar AN; Davidson SA; Dutta S; Griffith ME; Magee CD; Wojnarski M; Livezey JR; Kress AT; Waterman PE; Jongert E; Wille-Reece U; Volkmuth W; Emerling D; Robinson WH; Lievens M; Morelle D; Lee CK; Yassin-Rajkumar B; Weltzin R; Cohen J; Paris RM; Waters NC; Birkett AJ; Kaslow DC; Ballou WR; Ockenhouse CF; Vekemans J
J Infect Dis; 2016 Sep; 214(5):762-71. PubMed ID: 27296848
[TBL] [Abstract][Full Text] [Related]
5. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.
Rampling T; Ewer KJ; Bowyer G; Bliss CM; Edwards NJ; Wright D; Payne RO; Venkatraman N; de Barra E; Snudden CM; Poulton ID; de Graaf H; Sukhtankar P; Roberts R; Ivinson K; Weltzin R; Rajkumar BY; Wille-Reece U; Lee CK; Ockenhouse CF; Sinden RE; Gerry S; Lawrie AM; Vekemans J; Morelle D; Lievens M; Ballou RW; Cooke GS; Faust SN; Gilbert S; Hill AV
J Infect Dis; 2016 Sep; 214(5):772-81. PubMed ID: 27307573
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of RTS,S/AS01
Samuels AM; Ansong D; Kariuki SK; Adjei S; Bollaerts A; Ockenhouse C; Westercamp N; Lee CK; Schuerman L; Bii DK; Osei-Tutu L; Oneko M; Lievens M; Attobrah Sarfo MA; Atieno C; Morelle D; Bakari A; Sang T; Jongert E; Kotoh-Mortty MF; Otieno K; Roman F; Buabeng PBY; Ntiamoah Y; Ofori-Anyinam O; Agbenyega T;
Lancet Infect Dis; 2022 Sep; 22(9):1329-1342. PubMed ID: 35753316
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
Stewart VA; McGrath SM; Walsh DS; Davis S; Hess AS; Ware LA; Kester KE; Cummings JF; Burge JR; Voss G; Delchambre M; Garçon N; Tang DB; Cohen JD; Heppner DG
Vaccine; 2006 Oct; 24(42-43):6483-92. PubMed ID: 16904798
[TBL] [Abstract][Full Text] [Related]
12. The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants.
Ajua A; Lell B; Agnandji ST; Asante KP; Owusu-Agyei S; Mwangoka G; Mpina M; Salim N; Tanner M; Abdulla S; Vekemans J; Jongert E; Lievens M; Cambron P; Ockenhouse CF; Kremsner PG; Mordmüller B
Malar J; 2015 Feb; 14():72. PubMed ID: 25885325
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.
RTS,S Clinical Trials Partnership
PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396
[TBL] [Abstract][Full Text] [Related]
14. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
[TBL] [Abstract][Full Text] [Related]
15. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial.
Olotu A; Lusingu J; Leach A; Lievens M; Vekemans J; Msham S; Lang T; Gould J; Dubois MC; Jongert E; Vansadia P; Carter T; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Lapierre D; Ballou WR; Cohen J; Lemnge MM; Peshu N; Marsh K; Riley EM; von Seidlein L; Bejon P
Lancet Infect Dis; 2011 Feb; 11(2):102-9. PubMed ID: 21237715
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.
Stewart VA; Walsh DS; McGrath SM; Kester KE; Cummings JF; Voss G; Delchambre M; Garçon N; Cohen JD; Heppner DG
Vaccine; 2006 Oct; 24(42-43):6493-502. PubMed ID: 16911849
[TBL] [Abstract][Full Text] [Related]
18. RTS,S/AS01
Suau R; Vidal M; Aguilar R; Ruiz-Olalla G; Vázquez-Santiago M; Jairoce C; Nhabomba AJ; Gyan B; Dosoo D; Asante KP; Owusu-Agyei S; Campo JJ; Izquierdo L; Cavanagh D; Coppel RL; Chauhan V; Angov E; Dutta S; Gaur D; Beeson JG; Moncunill G; Dobaño C
Vaccine; 2021 Jan; 39(4):687-698. PubMed ID: 33358704
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.
Bejon P; Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Mshamu S; Lang T; Gould J; Dubois MC; Demoitié MA; Stallaert JF; Vansadia P; Carter T; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; von Seidlein L
N Engl J Med; 2008 Dec; 359(24):2521-32. PubMed ID: 19064627
[TBL] [Abstract][Full Text] [Related]
20. A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults.
Cummings JF; Polhemus ME; Kester KE; Ockenhouse CF; Gasser RA; Coyne P; Wortmann G; Nielsen RK; Schaecher K; Holland CA; Krzych U; Tornieporth N; Soisson LA; Angov E; Heppner DG;
Vaccine; 2024 Apr; 42(12):3066-3074. PubMed ID: 38584058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
